Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’

Table 2 Changes in measured clinical variables from baseline to study completion

Measured disease parameter(s)	Randomization		p-value (95% CI)
	Drug intervention (n = 132)	Placebo intervention (n = 127)
TB Severity (clinical assessment)
Mean Δ in TB score (points) ± SD, (95 CI)	- 3.19 ± 2.37, (−3.61, -2.75)	- 2.79 ± 2.44, (−3.23, -2.34)	0.198
Mean Δ in weight (kg), (95% CI)	+ 4.02, (3.18 – 4.86)	+ 2.61, (1.99 – 3.23)	0.007
Mean Δ in BMI, (95% CI)	+ 1.48, (1.17 – 1.78)	+ 0.96, (0.72 – 1.20)	0.008
Mean Δ in MUAC (cm), (95% CI)	+ 1.34, (0.74 – 1.64)	+ 0.97, (0.68 – 1.26)	0.079
Chest X-Ray Involvement
Mean no. of zones¹ involved ± SD	1.35 ± 1.13	1.82 ± 1.35	0.004
Sputum Smear
Smear Conversion, no. (%) ²	108 (81.8)	103 (81.1)	0.39
IFN-g levels (pg/ml) mean ± SD
Unstimulated levels	3.9 ±28.7	4.3 ± 45.2	0.325
ESAT6-stimulated*	387 ±920	206 ±665	0.077
MTBs-stimulated*	3092 ±1363	2987 ±1510	0.497

MUAC Mid Upper Arm Circumference; BMI Body Mass Index; 95 CI 95% Confidence Interval; SD Standard Deviation; s-25-(OH) D3 = serum 25-hydroxyvitamin D3.
¹ Division of bilateral ling fields into a total of 6 zones (3 per each lung, ‘zone involvement’ = active parenchymal and cavitary disease, exclusive of old fibrotic scarring. ² Includes all patients who were expectorating at baseline, and claimed ‘unable to expectorate’ at completion of treatment 12 weeks later. ESAT6 early secreted and T cell activated antigen-6 kDa; MTB_s Mycobacterium tuberculosis whole sonicate antigen.
*Denotes cytokine levels after subtraction of background from unstimulated cells.

ISSN: 1471-2334